Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo

The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design

(2013) Ruth Thompson et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias

(2012) J. E. Karp et al.   CLINICAL CANCER RESEARCH

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

(2012) Glen J. Weiss et al.   INVESTIGATIONAL NEW DRUGS

The Mre11 Nuclease Is Critical for the Sensitivity of Cells to Chk1 Inhibition

(2012) Ruth Thompson et al.   PLoS One

Variations in Mre11/Rad50/Nbs1 status and DNA damage-induced S-phase arrest in the cell lines of the NCI60 panel

(2011) Kristen M Garner et al.   BMC CANCER

Recombination phenotypes of the NCI-60 collection of human cancer cells

(2011) Dawn M Stults et al.   BMC MOLECULAR BIOLOGY

DNA damage-induced S phase arrest in human breast cancer depends on Chk1, but G2arrest can occur independently of Chk1, Chk2 or MAPKAPK2

(2011) Wen-Hui Zhang et al.   CELL CYCLE

Replication stress activates DNA polymerase alpha-associated Chk1

(2011) Lorena Taricani et al.   CELL CYCLE

Unleashing Chk1 in cancer therapy

(2011) Laura Carrassa et al.   CELL CYCLE

Assessment of Chk1 Phosphorylation as a Pharmacodynamic Biomarker of Chk1 Inhibition

(2011) L. A. Parsels et al.   CLINICAL CANCER RESEARCH

Targeting the S and G2 checkpoint to treat cancer

(2011) Tao Chen et al.   DRUG DISCOVERY TODAY

Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening

(2011) T. J. Guzi et al.   MOLECULAR CANCER THERAPEUTICS

Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and Antimetabolites

(2011) R. Montano et al.   MOLECULAR CANCER THERAPEUTICS

Structure-Specific DNA Endonuclease Mus81/Eme1 Generates DNA Damage Caused by Chk1 Inactivation

(2011) Josep V. Forment et al.   PLoS One

Hydroxyurea-Stalled Replication Forks Become Progressively Inactivated and Require Two Different RAD51-Mediated Pathways for Restart and Repair

(2010) Eva Petermann et al.   MOLECULAR CELL

DNA replication as a target of the DNA damage checkpoint

(2009) Philip Zegerman et al.   DNA REPAIR

A role for Chk1 in blocking transcriptional elongation of p21 RNA during the S-phase checkpoint

(2009) R. Beckerman et al.   GENES & DEVELOPMENT

Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells

(2009) L. A. Parsels et al.   MOLECULAR CANCER THERAPEUTICS

Chk1 phosphorylation at Ser286 and Ser301 occurs with both stalled DNA replication and damage checkpoint stimulation

(2008) Yosuke Ikegami et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage

(2008) E M Bahassi et al.   ONCOGENE